A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma

Trial Profile

A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Dec 2017

At a glance

  • Drugs Ipilimumab/nivolumab (Primary) ; Nivolumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Acronyms PRISM
  • Most Recent Events

    • 27 Dec 2017 According to ISRCTN95351638, the Recruitment start date for trial will be 31 Jan 2018 and Recruitment end date will be 31 Jan 2020.
    • 27 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top